Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand.

Pietzuch, Marlena; Mantel, Irmela; Ambresin, Aude; Tappeiner, Christoph; Nagyova, Dana; Donati, Guy; Pfister, Isabel B; Schild, Christin; Garweg, Justus G (2024). Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand. Journal of ocular pharmacology and therapeutics, 40(6), pp. 361-369. Mary Ann Liebert 10.1089/jop.2023.0105

[img] Text
pietzuch-et-al-2023-intravitreal-dexamethasone-as-a-rescue-for-anti-vascular-endothelial-growth-factor-therapy-in.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (442kB)

Purpose: To assess the impact of switching to, or adding, an intravitreal dexamethasone implant (Dex; Ozurdex®) in anti-vascular endothelial growth factor (VEGF) therapy on disease stability and treatment intervals in eyes with neovascular age-related macular degeneration (nAMD) and persistent disease activity and high treatment demand. Methods: This retrospective noncomparative multicenter longitudinal case series included pseudophakic eyes with nAMD and persistent retinal fluid despite regular anti-VEGF therapy (ranibizumab or aflibercept) that received at least 1 intravitreal Dex implant. Visual acuity, central retinal thickness (CRT), and intraocular pressure were recorded before, and after, the addition of Dex to anti-VEGF therapy. Results: Sixteen eyes of 16 patients met the inclusion criteria of persistent fluid despite anti-VEGF therapy, under treatment intervals of ≤7 weeks in 14 instances. Patients were 80.9 ± 7.4 years old and had received 25.5 ± 17.4 anti-VEGF injections before Dex over a period of 36.4 ± 21.9 months before switching. The treatment interval increased from 5.5 ± 3.2 weeks between the last anti-VEGF and first Dex injection to 11.7 ± 7.3 weeks thereafter (P = 0.022). CRT remained stable (385.3 ± 152.1, 383.9 ± 129.7, and 458.3 ± 155.2 μm before switching as well as 12 and 24 months after switching; P = 0.78 and P = 0.36, respectively). An insignificant mean short-term early increase in visual acuity was not sustained over time. Conclusions: The addition of Dex resulted in a relevant and sustained increase in treatment intervals, whereas CRT and visual acuity remained stable in these difficult-to-treat eyes. It may be discussed whether inflammation or other steroid-responsive factors play a significant role in cases of nAMD with nonsatisfactory responses to anti-VEGF.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Garweg, Justus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1080-7683

Publisher:

Mary Ann Liebert

Language:

English

Submitter:

Pubmed Import

Date Deposited:

21 Dec 2023 10:06

Last Modified:

23 Aug 2024 00:11

Publisher DOI:

10.1089/jop.2023.0105

PubMed ID:

38117666

Uncontrolled Keywords:

Ozurdex burden of treatment dexamethasone implant disease stability intravitreal anti-VEGF therapy neovascular age-related macular degeneration

BORIS DOI:

10.48350/190618

URI:

https://boris.unibe.ch/id/eprint/190618

Actions (login required)

Edit item Edit item
Provide Feedback